Atlas Trials

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

Clinical trial NCT02662062 · COMPLETED

Trial details

NCT number
NCT02662062
Sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2017-07-11
Primary completion
2022-05-12
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.